A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells.
about
Arsenic binding to proteinsIn situ imaging of metals in cells and tissuesMolecular profiling of signalling proteins for effects induced by the anti-cancer compound GSAO with 400 antibodies.Metabolism, toxicity and anticancer activities of arsenic compounds.Glutathione S-conjugates as prodrugs to target drug-resistant tumors.Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury.A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.Dual-targeting of aberrant glucose metabolism in glioblastomaMitochondrially targeted α-tocopheryl succinate is antiangiogenic: potential benefit against tumor angiogenesis but caution against wound healingThe tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase.A novel bifunctional mitochondria-targeted anticancer agent with high selectivity for cancer cells.Targeting of two aspects of metabolism in breast cancer treatment.Mitochondria: pharmacological manipulation of cell deathNecrotic platelets provide a procoagulant surface during thrombosisMitochondrial permeability transition pore as a selective target for anti-cancer therapyArsenic-based antineoplastic drugs and their mechanisms of action.1,1-bis(3'-indolyl)-1-(p-substituted phenyl)methanes decrease mitochondrial membrane potential and induce apoptosis in endometrial and other cancer cell linesA novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells.Darinaparsin: a novel organic arsenical with promising anticancer activity.Anticancer activity of metal complexes: involvement of redox processes.Targeting the mitochondrial permeability transition: cardiac ischemia-reperfusion versus carcinogenesis.Mitochondrial metabolism inhibitors for cancer therapy.Organometallic compounds: an opportunity for chemical biology?Therapeutic and analytical applications of arsenic binding to proteins.Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy.The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis.The mitochondrial permeability transition pore regulates endothelial bioenergetics and angiogenesis.Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study.Lonidamine causes inhibition of angiogenesis-related endothelial cell functions.Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.Elimination of the antimicrobial action of the organoarsenical cancer therapeutic, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, before finished product sterility testing.Mitochondria and Angiogenesis.Metabolism of the tumor angiogenesis inhibitor 4-(N-(S-Glutathionylacetyl)amino)phenylarsonous acid.Mitochondrial Changes in Cancer.VDAC1 as Pharmacological Target in Cancer and Neurodegeneration: Focus on Its Role in Apoptosis.Targeting Mitochondrial Ion Channels to Fight Cancer
P2860
Q28389752-2D524A8B-08A7-4815-8B81-0427B3BACC26Q28662002-34F76011-9C90-4E07-9BFE-76A6F040C1C3Q33246289-B4560361-3D81-4117-B604-ED3F9B01561CQ33618916-F7E6A9E0-9BDC-4738-9FB1-92CA8C562874Q34024771-E97F4F29-507C-47A4-9F3E-C69A97A28FBAQ34854255-4BE1E435-3251-4E91-853C-A31669028FF1Q35021208-4E161E14-627C-4F20-9650-887F3DA9403BQ35073645-104E24E8-DEA1-423D-AD00-973BDA847CF7Q35445080-EEAABEC8-471D-4C32-8CE1-0856F2F04B1DQ35950885-414DB20F-F91F-42FB-B37D-39FED9729132Q36026971-1717F074-62E0-4934-8920-886902E7AE1BQ36213008-ECF1083E-9B5E-4886-A66D-93ACD78299A6Q36274960-8F63033E-AD86-46B5-8EA3-B4FBC2A994C8Q36407002-8544DADC-BF8F-4807-A9E3-EBACDC0CCA83Q36668047-92B20687-3E96-46BD-9D7D-45A1B67E906AQ37145891-12EB99BE-C76E-4E9E-9FE0-8E319C6A1ADFQ37263942-2490699B-5047-44A1-A9B7-003AF3AB09EEQ37299473-48177E30-6593-4088-8A22-6DB107ADB859Q37603342-93DDD54D-05BB-47A5-8401-DEB799C8CB46Q37833099-83696B08-62CA-4CF8-8339-E8BE76B97414Q37862534-DE2CDE5D-394C-4EAC-A7CA-692B6AEA771DQ37932441-44DC9A2D-587C-42A8-AF37-1B9D5E77DA9EQ38012429-83A2A337-0E96-4FD8-92D3-D9CE9F0B28AFQ38263881-681835F1-4CF2-4DDD-8FFB-C4BC6CA5C0D9Q38741503-DE2768BD-5FE1-41F0-8CD4-6ED915F99499Q38974193-70ABD41F-E656-439C-AD14-97B276B59745Q39530881-C088AEE5-A247-40CE-9868-B1E301036FC7Q40469914-B7A2E888-C5B3-40D6-8880-EDEA0AD2CFDCQ40490910-4617A740-322A-43E7-BF47-0A77A9E31EF9Q41069547-2119DCB6-2EFD-4A75-86E3-269E461E369FQ45335104-B2D384DD-A68C-4687-9916-897EF48F5A60Q46359827-10C0AA95-C1A7-48A2-A75C-643173173F7AQ46413545-61F7287B-1D4F-4CCF-99D7-6E8B1E782D49Q46480305-12657BA5-05E4-45D3-B88E-E82F18EDC8AAQ55129102-CF9AE4AA-7FDC-4DB3-A373-8CCCAFAD8D2DQ57175954-56907061-0757-4D74-8172-E0D5F7AA030A
P2860
A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
A peptide trivalent arsenical ...... angiogenic endothelial cells.
@en
A peptide trivalent arsenical ...... angiogenic endothelial cells.
@nl
type
label
A peptide trivalent arsenical ...... angiogenic endothelial cells.
@en
A peptide trivalent arsenical ...... angiogenic endothelial cells.
@nl
prefLabel
A peptide trivalent arsenical ...... angiogenic endothelial cells.
@en
A peptide trivalent arsenical ...... angiogenic endothelial cells.
@nl
P2093
P1433
P1476
A peptide trivalent arsenical ...... n angiogenic endothelial cells
@en
P2093
Belinda Creighton
Evelyn Flynn
Judah Folkman
Neil Donoghue
Oliver Kisker
Philip J Hogg
Pierre Dilda
Stephanie Decollogne
Xueyun Zhao
P304
P356
10.1016/S1535-6108(03)00109-0
P577
2003-05-01T00:00:00Z